Roswell Park Comprehensive Cancer Center

Roswell Park-Led Research Reveals a Hidden Vulnerability of Lung Cancer

April 8th 2025

Sayan Chakraborty, PhD and team focus on targeting agrin, a protein that promotes treatment resistance/relapse.

Brain Imaging Plus Virtual Reality Shows Promise for Effectively Managing Cancer Pain

April 3rd 2025

Roswell Park-led study takes a significant step toward relief without opioid.

Society of Surgical Oncology Highlights Roswell Park Experts at 2025 Annual Meeting

March 25th 2025

Roswell Park Comprehensive Cancer Center surgeons will share their expertise during the 2025 annual meeting of the Society of Surgical Oncology.

Researchers Find Inherited Genetic Condition Raises Risk of Developing Two Rare Pediatric Cancers

March 6th 2025

Roswell Park’s Dr Kenan Onel leads large international team that sheds light on pineoblastoma and Wilms tumor.

Roswell Park Blood Cancer Expert Honored With Prestigious GVHD Research Award

February 19th 2025

The GVHD Alliance honored Shernan Holtan, MD, of Roswell Park Comprehensive Cancer Center, as the recipient of the 2025 Lukas D. Wartman Award.

Roswell Park-Led Team Proposes CDK2 Enzyme as New Target for Cancer Therapy

February 17th 2025

CDK2 regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs — including CDK4/6 inhibitors.

Roswell Park Team Identifies New Cause of Chemotherapy Resistance in Triple-Negative Breast Cancer

January 20th 2025

Laboratory research led by Anna Bianchi-Smiraglia, PhD, reveals therapeutic target in metabolic enzyme IMPDH2.

Preclinical Study Shows Targeted Drug Strengthens the Power of CAR T-Cell Therapy in Two Pediatric Leukemias

December 20th 2024

A preclinical study showed gilteritinib can strengthen CAR T-cell therapy in two high-risk pediatric leukemias.

Roswell Park Experts Present Evidence to Help Clinicians Advise Breast Cancer Survivors About Lifestyle Choices

December 16th 2024

Sessions at San Antonio Breast Cancer Symposium address exercise, cannabis, sexual health, plus insights on treatment.

Tomorrow’s Promise, Today’s Roswell Park: Leaders Tackling the Biggest Priorities in Cancer Care and Treatment

December 5th 2024

Roswell Park CEO Candace S. Johnson, PhD, introduces center’s first Physician in Chief, leaders in strategic areas

Roswell Park Clinical Trial Points Toward Promising New Therapy for Most Aggressive Type of Breast Cancer

November 28th 2024

A treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase 1 clinical trial for patients with TNBC.

Roswell Park Experts to Showcase Groundbreaking Hematology Research at 66th ASH Annual Meeting

November 25th 2024

More than a dozen teams to share advances in blood cancer treatment and research innovations at the 2024 ASH Annual Meeting.

Roswell Park Team Members Recognized for Exceptional Support to First Responders

November 19th 2024

Nurse-executive and partnership manager honored for dedication to local heroes.

New Computational Method Links One Mammal’s Striking Longevity and Resistance to Cancer With ‘Dark Genome’

October 30th 2024

A Roswell Park study reveals the evolutionary stability of the naked mole-rat’s genome, and implications for drug development.

Roswell Park Radiation Oncologist Highlights New Insights on Single-Fraction Radiation for Central Lung Tumors

October 16th 2024

Study featured at ASTRO 2024 is one of the first to assess single-fraction SBRT for centrally located lung cancers

Study Highlights Promising New Treatment Option for Patients With Treatment-Resistant Acute Myeloid Leukemia

October 11th 2024

Roswell Park’s Dr. Eunice Wang led KOMET-001 clinical trial; results newly reported in The Lancet Oncology.

Roswell Park–Designed Treatment Regimen Doubles Progression-Free Survival in Metastatic Kidney Cancer

October 1st 2024

Disparities Narrowing Among Patients Undergoing Blood Stem Cell Transplant, Roswell Park Study Reveals

September 24th 2024

Black patients and older adults are least likely to undergo this treatment for blood cancers and hematologic disorders.

Roswell Park Again Named a Top 10 New York State Employer by Forbes

August 30th 2024

Third year in a row cancer center has been ranked on this listing, based on employee surveys.

Final Results of Phase 2 Clinical Trial Clarify Role of JAK2 Inhibitor in Combating Acute Graft-Versus-Host Disease

August 23rd 2024

A study demonstrates that adding a JAK2 inhibitor to standard immunosuppressive drugs does not improve prevention of acute graft-versus-host disease.